Highlights of weekly biotech stock moves

Stocks for at least three companies moved last week following clinical and regulatory news for pulmonary arterial hypertension (PAH) products.

Actelion Ltd. (SIX:ATLN) shed CHF2.28 to CHF44.87 after submitting an NDA to FDA for Opsumit macitentan for PAH and announcing the compound led to a significant baseline-adjusted, placebo-corrected mean increase in 6-minute walk distance (6MWD) of 23 meters at six months in the Phase III SERAPHIN trial. Actelion previously said Opsumit met the primary endpoint of reducing a composite of time to first morbidity or mortality event vs. placebo (see B16). ...